No Data
No Data
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating, Announces Target Price $45
Insider Sale: Chief Commercial Officer of $SRRK Sells 5,000 Shares
Scholar Rock Application for Spinal Muscular Atrophy Treatment Gets FDA Approval
Scholar Rock Announces FDA Priority Review Designation For Apitegromab - Quick Facts
Scholar Rock Holding Corporation Says FDA Grants Priority Review For Biologics License Application And EMA Accepts Marketing Authorisation Application For Apitegromab As A Treatment For Spinal Muscular Atrophy
Express News | Scholar Rock Holding Corp - Plans U.S. Commercial Launch in 2025